Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 29;10(9):e005052. doi: 10.1136/jitc-2022-005052

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Assessment of baseline peripheral immune cell function in response to lerapolturev. PBMCs from the pretreatment time point were challenged with laboratory grade PVSRIPO in vitro for 24 hours. Supernatant was tested for proinflammatory cytokines. Patients in red have median PFS of 2.3 years after lerapolturev and patients in black have median PFS 1.6 months after lerapolturev. Data brackets indicate mean ±SEM; p values are from unpaired t-test. See online supplemental figure S3 for complete results of cytokines and stimuli tested; online supplemental figure S4 presents baseline raw MFI and concentration of cytokines for all stimuli. GMCSF, granulocyte-macrophage colony-stimulating factor; MFI, mean fluorescence intensity; PBMCs, peripheral blood mononuclear cells; PFS, progression-free survival.